ALX 0171

Drug Profile

ALX 0171

Alternative Names: ALX-0171; Anti-RSV nanobody; VR 465

Latest Information Update: 05 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Ablynx
  • Class Antivirals; Proteins
  • Mechanism of Action Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Respiratory syncytial virus infections

Most Recent Events

  • 06 Sep 2017 Ablynx intends to initiate file for a phase II trial in Respiratory syncytial virus infections (In infants) for regulatory approval in Japan in Q4 2017 and commence the trial in H1 2018
  • 21 Mar 2017 Ablynx exercises its option in the agreement with Vectura for continued development of ALX 0171 in hospitalised infants
  • 26 Sep 2016 Ablynx initiates a phase II trial for Respiratory syncytial virus infections (In infants) in Hungary and Estonia (EudraCT2016-001651-49)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top